Welcome to our dedicated page for Vitrolife news (Ticker: VTRLY), a resource for investors and traders seeking the latest updates and insights on Vitrolife stock.
The VTRLY news page tracks company communications and market-facing updates related to Vitrolife AB (publ), a biotechnology group active in reproductive health. Investors can use this feed to follow how the Vitrolife Group reports on its regional and product group performance, as well as strategic and financing developments that may influence the underlying business.
Vitrolife AB (publ) regularly publishes interim reports that detail sales in local currencies across EMEA, Americas and APAC, and across its Consumables, Technologies and Genetics product groups. These reports discuss organic growth excluding discontinued business, currency effects on sales and margins, gross margin levels, EBITDA, operating cash flow and net income. News items linked to these reports often include conference call invitations, where management presents the results and answers questions from investors, analysts and financial media.
The news flow also covers strategic initiatives and organisational changes. For example, Vitrolife AB (publ) has announced that it became a leading investor in AutoIVF, an early-stage MedTech company focused on making IVF more accessible, affordable and efficient through its OvaReady™ technology. The company has also communicated changes to its Executive Management Team, including the introduction of a SVP Innovation role to oversee R&D, Strategy & Sustainability, Portfolio Lifecycle Management and Market Access.
Governance and capital structure events appear in the form of Annual General Meeting notices and reports, which describe proposed and approved dividends, Board elections, auditor re-elections, share issue and share repurchase authorisations and share-based incentive programs. Financing news includes announcements such as the renewal and signing of a loan agreement comprising a term loan and revolving credit facility backed by Nordic banks.
By reviewing the VTRLY news feed, readers can follow how Vitrolife AB (publ) communicates on financial performance, IVF-related strategic investments, executive appointments, governance decisions and loan facilities. This makes the page a useful reference for anyone monitoring the company’s publicly disclosed developments over time.
Vitrolife AB (OTC-PINK:VTRLY) has announced a conference call scheduled for February 2, 2023, at 10:00 a.m. CET, to present its Year-end report for 2022. Participants include CEO Thomas Axelsson and CFO Patrik Tolf. The press release for the report will be available at 8:00 a.m. CET on the same day. Interested parties can register for the call via a provided link, which will give access to necessary dial-in information. A recorded version of the call will be accessible for seven days post-event. For additional information, presentation materials will be available on the company's investor webpage.
Vitrolife's CEO Thomas Axelsson has acquired 12,000 shares valued at 2,124,000 SEK, increasing his total holdings to 25,000 shares. This significant purchase reflects confidence in the company's future performance. The transaction will comply with regulations outlined by the Swedish Financial Supervisory Authority and was disclosed on October 28, 2022. The information is part of Vitrolife's obligations under the EU Market Abuse Regulation.
On October 28, 2022, Thomas Axelsson, CEO of Vitrolife, acquired 12,000 shares valued at 2,124,000 MSEK, increasing his total holdings to 25,000 shares. This transaction adheres to regulatory requirements and will be reported to the Swedish Financial Supervisory Authority. The information is disclosed under the EU Market Abuse Regulation and the Securities Markets Act, ensuring compliance and transparency regarding executive stock purchases.
GOTHENBURG, Sweden, Oct. 27, 2022 /PRNewswire/ -- Vitrolife AB reported Q3 sales of SEK 798 million, a 97% increase, primarily driven by acquisitions and currency effects. Consumables sales rose 18%, while Genetic Services generated SEK 348 million. EBITDA was SEK 276 million, with a margin of 34.5%, though down from 40%. Net income reached SEK 108 million, with earnings per share at SEK 0.80. Year-to-date sales totaled SEK 2,379 million, a 104% increase. Restructuring costs totaled SEK 31 million, impacting EBITDA and financial results.
Vitrolife AB invites investors to attend a conference call on October 27, 2022, at 10:00 a.m. CET, to discuss the interim report for the period of January to September 2022. Registrations can be completed 10-15 minutes prior using provided local and international dial-in numbers. The interim report will be released at 8:00 a.m. CET on the same day. Presentation materials will be available on the company's website prior to the call. A recorded version will also be accessible for seven days post-conference.
Vitrolife has appointed members to its election committee ahead of the Annual General Meeting on April 27, 2023. The committee includes Niels Jacobsen from William Demant Invest A/S, Patrik Tigerschiöld from Bure Equity AB, and Erika Henriksson from EQT VIII, along with Chairman Jón Sigurdsson. These appointments align with guidelines set at the previous year's meeting. Shareholders can propose agenda items by submitting requests to the Board by mid-March 2023.
Thomas Axelsson, CEO of Vitrolife AB, announced his intention to retire, prompting the Board of Directors to begin the search for a successor. Axelsson has served as CEO since 2011, leading the company through profitable growth and significant value creation. Jon Sigurdsson, Chairman of the Board, will oversee the CEO recruitment process while Axelsson remains in his role until a new leader is appointed. The transition aims to ensure consistency and continuity within the organization. Vitrolife Group specializes in medical devices and genetic services to enhance fertility treatments.
VITROLIFE AB reported substantial growth in its Q2 and first half of 2022 financial results, with sales reaching SEK 829 million, a 117% year-on-year increase. Of this growth, 80% was attributed to acquisitions. Net income rose to SEK 130 million with earnings per share of SEK 0.96. The Americas saw remarkable sales growth of 241%.
However, EBITDA margin slightly decreased to 32.9% from 35.2% in Q2. For the first half, total sales reached SEK 1,581 million, with EBITDA margin also falling to 31.7%.
Vitrolife invites participants to its conference call on July 15, 2022, at 10:00 a.m. CET to discuss the interim report for January – June 2022. The call will feature Thomas Axelsson, CEO, and Patrik Tolf, CFO. Interested parties can register 10-15 minutes before the start time using provided dial-in numbers. A press release detailing the interim report will be accessible at 8:00 a.m. CET on the same day. A recorded version of the call will be available for seven days afterward.
VITROLIFE AB reported a strong first quarter for 2022, with sales reaching SEK 752 million, an increase of 98%. Key drivers included 74% growth from acquisitions and 11% organic growth. All regions saw strong performance, particularly the Americas at 255%. EBITDA rose to SEK 228 million with a margin of 30.4%, while net income was SEK 82 million, down from SEK 119 million year-over-year. Adjusted sales, excluding Covid-related business, increased by 18%.